Two injections, two entirely different jobs

Most people searching for 'the best cartilage injection for the knee' expect a head-to-head comparison. Clinicians, however, are asking a prior question: what kind of cartilage problem does this person actually have?

ChondroFiller is a collagen scaffold placed into a discrete, focal cartilage defect — a contained lesion, typically confirmed on MRI, in an otherwise structurally reasonable joint. Hyaluronic acid (HA) viscosupplementation works across the whole joint surface, replenishing degraded synovial fluid to reduce friction-related pain in diffuse osteoarthritis. One addresses a structural cavity; the other addresses a lubrication deficit. They are not rival answers to the same question.

Patient selection is the clinical driver, not product preference. Depending on what imaging reveals, a patient may be right for ChondroFiller, right for HA, or — where a focal defect coexists with broader joint degeneration — potentially right for both through separate, complementary pathways. Neither injection is a universal solution, and neither substitutes for the other where the underlying diagnosis is different.

What ChondroFiller does inside a focal cartilage defect

Placed directly into a focal cartilage lesion under ultrasound guidance, ChondroFiller Liquid is a native Type I collagen hydrogel — CE-marked as a Class III implantable medical device, the regulatory tier reserved for materials that interact directly with body tissue. The treatment is an outpatient injection appointment; there is no incision, no arthroscopy, and no general anaesthetic.

Once positioned inside the defect cavity — identified and sized on MRI before the appointment — the liquid self-gels within approximately three to five minutes, forming a stable, three-dimensional fibrillar matrix that conforms to the contours of the lesion.

The scaffold's role is then biological rather than purely mechanical. In a process called acellular matrix-induced chondrogenesis, the collagen structure draws the patient's own progenitor cells — recruited from the surrounding synovium and subchondral bone — into the defect space. Those cells produce new collagen and glycosaminoglycans, the building blocks of cartilage matrix. A 2025 ex vivo study confirmed this recruitment: DNA content within ChondroFiller scaffolds increased 2.4-fold by day 14, with significant correlations between cell density and collagen production.

Over one to two years, the original collagen scaffold is progressively resorbed as endogenous repair tissue replaces it. This makes ChondroFiller a single-course treatment rather than a repeating palliative cycle. The mechanism depends on a viable progenitor cell environment near the defect site, which is why pre-existing advanced osteoarthritis is a recognised contraindication.

What hyaluronic acid does (and doesn't do)

Hyaluronic acid (HA) injections work by replenishing degraded synovial fluid. In a healthy knee, naturally occurring hyaluronan gives the fluid its viscosity and lubricating properties; in osteoarthritis, both its concentration and molecular weight fall, leaving joint surfaces less well protected during movement. HA viscosupplementation restores that lubrication across the whole joint surface.

The benefit is symptomatic. Reduced friction means less pain during movement, and some patients also notice reduced stiffness. Critically, HA does not deposit any material into a structural defect, does not recruit repair cells, and does not alter the integrity of the cartilage surface — a distinction that becomes decisive when deciding whether HA is appropriate for a given patient. Effects are temporary; repeat courses roughly every six months are typical for patients who continue to respond well.

The indicated population is mild-to-moderate diffuse osteoarthritis — broadly Kellgren-Lawrence Grade II–III — where the primary problem is joint-wide synovial fluid degradation rather than a contained structural lesion. In that group, a substantial body of evidence, including multiple systematic reviews and meta-analyses, confirms meaningful symptomatic value.

Guideline bodies disagree, however, on how strongly to endorse it. OARSI offers conditional support for HA in knee OA; AAOS and ACR are more sceptical, pointing to inconsistency across trials. In practice, that disagreement means HA sits as one considered option rather than an automatic first-line standard — clinicians weigh it alongside other approaches for each patient rather than applying it categorically. Molecular weight is sometimes raised as a practical variable, with higher-molecular-weight formulations (such as Hylan G-F 20) proposed to offer more durable lubrication, though head-to-head trial comparisons are complicated by methodological variation across studies.

Which patients are typically assessed for each — and when both apply

The clearest way to think about patient selection is to ask what the imaging actually shows.

Focal, contained cartilage lesion — typically Grade III–IV in depth, up to around 6 cm², in an otherwise structurally sound joint. ChondroFiller is usually the clinical question worth exploring. A collagen scaffold can fill a defined defect cavity and recruit the patient's own repair cells; lubrication alone cannot bridge a structural gap.

Diffuse cartilage thinning across the joint surface — broadly Kellgren-Lawrence Grade II–III osteoarthritis — points toward HA viscosupplementation or other palliative and biologic options. The problem is joint-wide rather than contained, and a focal scaffold cannot address broad-surface degeneration.

Pre-existing advanced OA is a ChondroFiller contraindication, even when a focal lesion is also visible. A hip arthroscopy cohort published in the Journal of Hip Preservation Surgery found poor outcomes in patients with Tönnis Grade 2–3 disease — attributed to the reduced progenitor cell environment near the defect that the scaffold mechanism depends on.

One practical point to raise at any assessment: a biomechanical study found ChondroFiller shows initial instability under cyclic load, so delayed weight-bearing after the injection is clinically recommended. Patients should ask their assessing clinician what the expected mobility timeline looks like for their defect size and site.

Where a focal defect and background OA coexist, a combined pathway called CFI+ has been proposed — ChondroFiller (the regenerative collagen scaffold) alongside Arthrosamid (a non-regenerative polyacrylamide hydrogel targeting synovial symptoms). The two products act through different mechanisms and are not interchangeable. Direct combination evidence remains limited, and individual clinical assessment determines whether the approach is appropriate.

What the evidence currently shows — and where gaps remain

The clinical trial record for ChondroFiller is small but mechanistically coherent. The 2016 randomised controlled trial enrolled 23 patients (13 ChondroFiller, 10 microfracture); IKDC scores improved significantly at three and six months (p<0.05) and held at 12 months, with MRI confirming good defect filling and scaffold integration and no adverse events recorded. A 2024 knee cohort (n=17, mean age 31) reproduced the pattern — significant improvements in both Lysholm and IKDC scores at three, six, and 12 months, with results stabilising between the latter two time points. Published series report approximately 30-point IKDC improvements and MOCART scores of 70–87 in treated cohorts.

Those figures come from studies of 13 to 26 patients, which is a real limitation: the sample sizes can support proof-of-concept findings but not the statistical power to establish long-term durability across diverse presentations. The 2025 ex vivo work noted in the earlier section on mechanism supports the scaffold's cell-recruitment claims; it is mechanistic evidence, not clinical outcome data, and should be understood as such — a useful foundation, not a substitute for larger trial results.

Hyaluronic acid's evidence base is substantially larger — multiple systematic reviews and meta-analyses confirm symptomatic benefit in diffuse mild-to-moderate OA, even where guideline bodies differ on the weight of that recommendation.

No head-to-head RCT comparing ChondroFiller with HA in matched populations exists. Given the categorical difference in what the two treatments address, designing one would require identifying patients who genuinely fit both profiles simultaneously. For a patient approaching a specialist, the practical implication is that the evidence asymmetry — large and contested for HA, small and encouraging for ChondroFiller — means imaging findings and dominant pathology are the more productive frame for that conversation than any general product comparison.

Finding the right specialist for a cartilage injection assessment

Bringing existing MRI and X-ray reports to a first consultation moves the appointment straight to clinical decision-making rather than scene-setting. The diagnostic split — focal, contained lesion versus diffuse joint-wide degeneration — is not something an assessing clinician can resolve from a symptom description alone; imaging is the starting point.

Specialist background matters. MSK physicians and orthopaedic consultants with specific experience in cartilage injection pathways will be familiar with the defect grading and size criteria that separate scaffold candidacy from viscosupplementation. Search MSK lists specialists across the UK who offer ChondroFiller and related cartilage injection assessments — filterable by region and specialty.

The clearest question to bring to that appointment: "Based on my imaging, am I a candidate for a structural scaffold injection or a viscosupplement — and why?" That question puts diagnosis, not product preference, at the centre of the conversation — which is exactly where it belongs.